U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 1506

1.
Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy
Phyu Sin Aye, Joanne Barnes, George Laking, Laird Cameron, Malcolm Anderson, Brendan Luey, Stephen Delany, Dean Harris, Blair McLaren, Elliott Brenman, Jayden Wong, Ross Lawrenson, Michael Arendse, Sandar Tin Tin, Mark Elwood, Philip Hope, Mark James McKeage
JMIR Res Protoc. 2024; 13: e51381. Published online 2024 Jul 2. doi: 10.2196/51381
PMCID:
PMC11252616
AbstractArticle
2.
Radiation-Activated Cobalamin-Kinase Inhibitors for Treatment of Pancreatic Ductal Adenocarcinoma
Liberty N. Gendron, Colter G. Sheveland, Jason R. Gunn, Brian W. Pogue, Thomas A. Shell, Jennifer R. Shell
Mol Pharm. Author manuscript; available in PMC 2024 Jul 8.
Published in final edited form as: Mol Pharm. 2024 Jan 1; 21(1): 137–142. Published online 2023 Nov 21. doi: 10.1021/acs.molpharmaceut.3c00667
PMCID:
PMC11228961
AbstractArticlePDF–714K
3.
EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266–283 antitumor response in preclinical glioblastoma models
Andrea Álvarez-Vázquez, Laura San-Segundo, Pilar Cerveró-García, Raquel Flores-Hernández, Claudia Ollauri-Ibáñez, Berta Segura-Collar, Christopher G Hubert, Gillian Morrison, Steven M Pollard, Justin D Lathia, Pilar Sánchez-Gómez, Arantxa Tabernero
Neuro Oncol. 2024 Jul; 26(7): 1230–1246. Published online 2024 Mar 20. doi: 10.1093/neuonc/noae060
PMCID:
PMC11226870
AbstractArticlePDF–29M
4.
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World
Giulia Pasello, Martina Lorenzi, Daniela Scattolin, Alessandro Del Conte, Fabiana Cecere, Alberto Pavan, Marianna Macerelli, Valentina Polo, Sara Pilotto, Mariacarmela Santarpia, Enrico Cumerlato, Valentina Da Ros, Giada Targato, Alberto Bortolami, Laura Bonanno, Alessandra Ferro, Alessandro Dal Maso, Stefano Frega, Valentina Guarneri
Oncologist. 2024 Jul; 29(7): 596–608. Published online 2024 Mar 23. doi: 10.1093/oncolo/oyae043
PMCID:
PMC11224988
AbstractArticlePDF–5.4M
5.
Preparation of Erlotinib hydrochloride nanoparticles (anti-cancer drug) by RESS-C method and investigating the effective parameters
Majid Bazaei, Bizhan Honarvar, Nadia Esfandiari, Seyed Ali Sajadian, Zahra Arab Aboosadi
Sci Rep. 2024; 14: 14955. Published online 2024 Jun 28. doi: 10.1038/s41598-024-64477-8
PMCID:
PMC11213895
AbstractArticlePDF–3.0M
6.
A Novel Boron Dipyrromethene-Erlotinib Conjugate for Precise Photodynamic Therapy against Liver Cancer
Wenqiang Wu, Chengmiao Luo, Chunhui Zhu, Zhengyan Cai, Jianyong Liu
Int J Mol Sci. 2024 Jun; 25(12): 6421. Published online 2024 Jun 11. doi: 10.3390/ijms25126421
PMCID:
PMC11203698
AbstractArticlePDF–7.3M
7.
Susceptibility to natural killer cell‐mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16‐binding protein‐1 induction
Jae‐Ho Bae, So‐Jung Kim, Mi‐Ju Kim, Sae‐Ock Oh, Joo‐Seop Chung, Sun‐Hee Kim, Chi‐Dug Kang
Cancer Sci. 2012 Jan; 103(1): 7–16. Published online 2011 Nov 15. doi: 10.1111/j.1349-7006.2011.02109.x
PMCID:
PMC11164140
AbstractArticlePDF–802K
8.
Substrate‐dependent bidirectional modulation of P‐glycoprotein‐mediated drug resistance by erlotinib
Kohji Noguchi, Haruka Kawahara, Airi Kaji, Kazuhiro Katayama, Junko Mitsuhashi, Yoshikazu Sugimoto
Cancer Sci. 2009 Sep; 100(9): 1701–1707. Published online 2009 May 12. doi: 10.1111/j.1349-7006.2009.01213.x
PMCID:
PMC11159693
AbstractArticlePDF–1.3M
9.
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplification
Takeshi Yoshida, Isamu Okamoto, Wataru Okamoto, Erina Hatashita, Yuki Yamada, Kiyoko Kuwata, Kazuto Nishio, Masahiro Fukuoka, Pasi A. Jänne, Kazuhiko Nakagawa
Cancer Sci. 2010 Jan; 101(1): 167–172. Published online 2009 Sep 14. doi: 10.1111/j.1349-7006.2009.01368.x
PMCID:
PMC11158912
AbstractArticlePDF–505K
10.
Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation‐targeted lung cancer therapy
Hongbin Ji
Cancer Sci. 2010 Sep; 101(9): 1933–1938. Published online 2010 May 22. doi: 10.1111/j.1349-7006.2010.01629.x
PMCID:
PMC11158733
AbstractArticlePDF–307K
11.
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines
Irene V. Bijnsdorp, Frank A. E. Kruyt, Masakazu Fukushima, Kees Smid, Shanti Gokoel, Godefridus J. Peters
Cancer Sci. 2010 Feb; 101(2): 440–447. Published online 2009 Sep 29. doi: 10.1111/j.1349-7006.2009.01375.x
PMCID:
PMC11158490
AbstractArticlePDF–528K
12.
Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case Report
Tatsuya Yazaki, Masanobu Kimoto, Ayumi Minagawa, Takashi Maruno, Miwa Yamanaka, Kei Sonehara, Mineyuki Hama, Toshitsugu Nakamura, Shintaro Kanda, Masayuki Hanaoka, Tsutomu Hachiya
Am J Case Rep. 2024; 25: e943466-1–e943466-7. Published online 2024 Jun 1. doi: 10.12659/AJCR.943466
PMCID:
PMC11155200
AbstractArticlePDF–5.0M
13.
Imidazole[1,5-a]pyridine derivatives as EGFR tyrosine kinase inhibitors unraveled by umbrella sampling and steered molecular dynamics simulations
Duc Toan Truong, Kiet Ho, Huynh Thi Yen Nhi, Van Ha Nguyen, Tuan Thanh Dang, Minh Tho Nguyen
Sci Rep. 2024; 14: 12218. Published online 2024 May 28. doi: 10.1038/s41598-024-62743-3
PMCID:
PMC11133355
AbstractArticlePDF–5.4M
14.
In situ single-cell therapeutic response imaging facilitated by the TRIPODD fluorescence imaging platform
Nathan P. McMahon, Allison Solanki, Lei G. Wang, Antonio R. Montaño, Jocelyn A. Jones, Kimberley S. Samkoe, Kenneth M. Tichauer, Summer L. Gibbs
Theranostics. 2024; 14(7): 2816–2834. Published online 2024 Apr 29. doi: 10.7150/thno.93256
PMCID:
PMC11103495
AbstractArticlePDF–7.1M
15.
KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry‐based subtyping
Jia Rao, Marianne Sinn, Uwe Pelzer, Hanno Riess, Helmut Oettle, Ihsan E Demir, Helmut Friess, Carsten Jäger, Katja Steiger, Alexander Muckenhuber
J Pathol Clin Res. 2024 May; 10(3): e12377. Published online 2024 May 15. doi: 10.1002/2056-4538.12377
PMCID:
PMC11096282
AbstractArticlePDF–8.5M
16.
Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
Tetyana Bagnyukova, Brian L. Egleston, Valerii A. Pavlov, Ilya G. Serebriiskii, Erica A. Golemis, Hossein Borghaei
Cancer Res Commun. 2024 May; 4(5): 1227–1239. Published online 2024 May 8. doi: 10.1158/2767-9764.CRC-23-0482
PMCID:
PMC11078142
AbstractArticlePDF–11M
17.
Crystal structures of human NSDHL and development of its novel inhibitor with the potential to suppress EGFR activity
Dong-Gyun Kim, Sujin Cho, Kyu-Yeon Lee, Seung-Ho Cheon, Hye-Jin Yoon, Joo-Youn Lee, Dongyoon Kim, Kwang-Soo Shin, Choong-Hyun Koh, Ji Sung Koo, Yuri Choi, Hyung Ho Lee, Yu-Kyoung Oh, Yoo-Seong Jeong, Suk-Jae Chung, Moonkyu Baek, Kwan-Young Jung, Hyo Jin Lim, Hyoun Sook Kim, Sung Jean Park, Jeong-Yeon Lee, Sang Jae Lee, Bong-Jin Lee
Cell Mol Life Sci. 2021 Jan; 78(1): 207–225. Published online 2020 Mar 5. doi: 10.1007/s00018-020-03490-2
PMCID:
PMC11068002
AbstractArticlePDF–3.0M
18.
Decoding dynamic interactions between EGFR‐TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment
Rajesh Kumar Meher, Showkat Ahmad Mir, Kritika Singh, Nobendu Mukerjee, Binata Nayak, Ajoy Kumer, Torki A. Zughaibi, Mohd Shahnawaz Khan, Shams Tabrez
J Cell Mol Med. 2024 May; 28(9): e18263. Published online 2024 Apr 29. doi: 10.1111/jcmm.18263
PMCID:
PMC11058330
AbstractArticlePDF–4.3M
19.
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
David A. Smith, Paul Conkling, Donald A. Richards, John J. Nemunaitis, Thomas E. Boyd, Alain C. Mita, Guillaume de La Bourdonnaye, David Wages, Alice S. Bexon
Cancer Immunol Immunother. 2014 Aug; 63(8): 787–796. Published online 2014 Apr 27. doi: 10.1007/s00262-014-1547-6
PMCID:
PMC11028443
AbstractArticlePDF–270K
20.
Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib
Anyue Yin, G. D. Marijn Veerman, Johan G. C. van Hasselt, Christi M. J. Steendam, Hendrikus Jan Dubbink, Henk‐Jan Guchelaar, Lena E. Friberg, Anne‐Marie C. Dingemans, Ron H. J. Mathijssen, Dirk Jan A. R. Moes
CPT Pharmacometrics Syst Pharmacol. 2024 Apr; 13(4): 612–623. Published online 2024 Feb 20. doi: 10.1002/psp4.13105
PMCID:
PMC11015077
AbstractArticlePDF–505K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center